We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Evaluation Of Severe Sepsis And Septic Shock. Procalcitonin Versus Delta Sofa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01841190
Recruitment Status : Unknown
Verified March 2013 by José Raimundo Araujo de Azevedo, Hospital Sao Domingos.
Recruitment status was:  Recruiting
First Posted : April 26, 2013
Last Update Posted : April 26, 2013
Sponsor:
Information provided by (Responsible Party):
José Raimundo Araujo de Azevedo, Hospital Sao Domingos

Brief Summary:
The purpose of this study is to compare the tendency of plasma concentration and clearance of procalcitonin in the first 24 and 48 hours of management of patients with severe sepsis and septic shock with another marker of early prognosis represented by 48 hours delta sofa.

Condition or disease
Severe Sepsis Septic Shock

Detailed Description:
This is a cohort prospective observational study that will include adult patients admitted to a multidisciplinary ICU of a tertiary hospital.

Study Type : Observational
Estimated Enrollment : 128 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: PROGNOSTIC EVALUATION OF SEVERE SEPSIS AND SEPTIC SHOCK. PROCALCITONIN VERSUS DELTA SOFA
Study Start Date : May 2012
Primary Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis Shock
U.S. FDA Resources

Group/Cohort
PROCALCITONIN
DELTA SOFA



Primary Outcome Measures :
  1. MORTALITY [ Time Frame: 28 DAYS ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients with severe sepsis and septic shock admitted to a multidisciplinary ICU
Criteria

Inclusion Criteria:

  • Adult patients admitted to the ICU
  • severe sepsis and septic shock

Exclusion Criteria:

  • Children
  • Pregnant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01841190


Contacts
Contact: JOSE R AZEVEDO, MD 55 98 32168110 jrazevedo@elo.com.br

Locations
Brazil
Hospital Sao Domingos Recruiting
Sao Luis, Maranhao, Brazil, 65060-642
Contact: ORLANDO J TORRES, PhD    559832168100    o.torres@uol.com.br   
Hospital Sao Domingos Recruiting
Sao Luis, MA, Brazil, 65060-642
Contact: JOSE R AZEVEDO, MD    55 98 32168110    jrazevedo@elo.com.br   
Principal Investigator: JOSE R AZEVEDO, MD         
Sponsors and Collaborators
Hospital Sao Domingos

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: José Raimundo Araujo de Azevedo, MD. COORDINATOR. ICU., Hospital Sao Domingos
ClinicalTrials.gov Identifier: NCT01841190     History of Changes
Other Study ID Numbers: hsd1509
First Posted: April 26, 2013    Key Record Dates
Last Update Posted: April 26, 2013
Last Verified: March 2013

Keywords provided by José Raimundo Araujo de Azevedo, Hospital Sao Domingos:
Prognosis
Sepsis
Septic shock
Procalcitonin
SOFA

Additional relevant MeSH terms:
Sepsis
Toxemia
Shock
Shock, Septic
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Calcitonin
Bone Density Conservation Agents
Physiological Effects of Drugs